Effects of rebreathing conditions and body size on normal human lung tissue volume

J.M. Polianski, P.D. Vivet, T.C. Chinet, S.I. Labrune, D.G. Henzel, G.J. Huchon

Effects of rebreathing conditions and body size on normal human lung tissue volume. J.M. Polianski, P.D. Vivet, T.C. Chinet, S.I. Labrune, D.G. Henzel, G.J. Huchon.

ABSTRACT: To evaluate the consequences of breathing pattern variations inherent to lung disease on the rebreathing measurement of lung tissue volume (Vt), we carried out a study of ten normal human subjects in whom we assessed the effects of changes in rebreathing volume (Vreb), additional deadspace volume (AVD), respiratory rate (RR), and body height. Vt and alveolar volume (VA) were determined from the end-tidal concentrations of acetylene and helium. We performed Vt measurements using different combinations of Vreb (20, 30 and 50% of predicted vital capacity), of AVD (0, 100, and 200 ml) and of RR (10, 25, and 40 br·min⁻¹). Only slow RR (10 br·min⁻¹) resulted in a higher Vt (p<0.001). An increase in Vreb induced an increase in VA but not in Vt. VA and Vt were positively correlated with the height of the subjects. We conclude that, in normal subjects, Vt increases: 1) with the height of subjects; and 2) when the respiratory rate is low. Interpretation of Vt results must take into account these two variables.

Eur Respir J., 1989, 2, 78-83.

Université René Descartes, Unité INSERM 214, Hôpital Laënnec, 75340 Paris Cedex 07 and Unité INSERM 13, Hôpital Claude Bernard, 75944 Paris Cedex 19, France.

Correspondence: G.J. Huchon, Hôpital Laënnec, 75340 Paris Cedex 07, France.

Keywords: Acetylene; deadspace; lung tissue volume; mass spectrometer, rebreathing volume; respiratory rate.

Accepted for publication July 30, 1988.

This work was supported by grants from the National Heart, Lung and Blood Institute HL 19155 (Pulmonary Vascular SCOR), from NATO 124182, and from INSERM 129052.

The inert gas rebreathing method is a noninvasive technique which provides an estimate of lung tissue volume (Vt) calculated from the rate of disappearance of a soluble gas from the alveolar spaces. Vt, which comprises both parenchymal tissue and blood, has been measured using this method in animals [1-6] and humans with normal and oedematous lungs [7-13]. Computer and mass spectrometry gas analysis measures Vt faster and more accurately than previous methods, because rebreathing can be substituted for breath-holding [1, 7, 9, 10, 14, 15]. In addition to the inherent inaccuracies due mainly to inhomogeneity of ventilation [16], theoretical and animal studies [1, 15, 17, 18], and one study in man [13] have shown that Vt depends on the pattern of rebreathing. The latter study reported that Vt increases with greater penetration of the inspired gas mixture into the lungs and that the time allowed for alveolar mixing is an important determinant of Vt.

We studied a group of normal untrained subjects with a large range of body heights to determine the effect of height on Vt. Because lung diseases may induce changes in Vt measurement, not corresponding to real changes in Vt but to changes in rebreathing conditions, we also assessed the effects on Vt of varying rebreathing volumes (Vreb), additional deadspaces (AVD) and respiratory rates (RR).

Materials and methods

Materials

The study design and technique were similar to those previously reported by Overland et al. [10]. Subjects rebreathed through a three-way valve (Hans-Rudolph 2770, Kansas-City, MO, USA) in a bag-bottle system filled with a gas mixture containing 0.5% acetylene (C₂H₂), 9.5% helium (He), 25% oxygen (O₂) and 65% nitrogen (N₂). Gas from the valve chamber was continuously sampled at a rate of 60 ml·min⁻¹ by a mass spectrometer (Centronic MGA 200, Croydon, England) with a 90% response time of 80 ms and a sampling delay of 540 ms. The rate of airflow in and out of the rebreathing bag was measured with a Fleisch No. 3 pneumotachograph (MSR, Paris, France) and a differential transducer (CH 5112/0 Enertec-Schlumberger, Vélizy-Villacoublay, France); the signal was amplified (CA 9036/0 Enertec-Schlumberger, Vélizy-Villacoublay, France) and integrated to provide a record of Vreb. The electrical outputs of the integrator and of the mass spectrometer were converted to digital data at a rate of 10 Hz per channel and stored for analysis in a PDP 11/23 computer (Digital Equipment Co., Maynard, MA, USA).

Calculations

Lung tissue volume (Vt) was calculated using the mathematical approach originally described by CANDER and Forster [14], as modified for the computer-assisted multiple rebreathing studies [7, 10]. "Alveolar" endexpiratory fractional concentrations of C2H2 relative to the concentration of the insoluble gas He were calculated for each of the first six breaths. Time zero was defined as the moment when one-half of the inspired Vreb became greater than the sum of the volumes of deadspace in the apparatus (107 ml) and the calculated deadspace in the subject's airways (body wt in kg: 2.2) [1]. The first end-expiratory fractional concentrations of each rebreathing study were discarded to minimize problems due to deadspace and mixing during the first breath; not doing so would increase variability in the measured Vt. We established a semilogarithmic plot against time of the second to sixth end-expiratory fractional concentrations of C2H2, in the system, and its intercept at time zero was calculated. We computed the alveolar volume (VA) as the total gas volume at the end of inspiration during the rebreathing manoeuvres minus the apparatus deadspace and subjects' calculated deadspace. Vt was calculated using the alveolar volume, the C₂H₂ lung tissue solubility established by CANDER [19], and the intercept, which is the extrapolated end- expiratory fractional concentration of C,H, relative to He at time zero [1, 14].

Experimental conditions

Ten normal healthy nonsmoking subjects agreed to participate in the study after having undergone informed consent procedures. All subjects had normal lung flows and volumes; age ranged 31–56 yrs (36±8 yrs), height 162–187 cm (171±9 cm) and weight 52–81 kg (65±10 kg). Each subject was studied under seven experimental

conditions to evaluate the effects of varying Vreb, AVD, and RR on Vt measurement. The "standard" experimental condition was defined as the following: Vreb equal to 35% of the subject's predicted vital capacity (VC), AVD equal to 0 ml (no additional deadspace), and RR equal to 25 br·min⁻¹. The six other experimental conditions were obtained by changing one of these three variables whilst keeping the other two constant. Vreb was, respectively, 20, 35 or 50% of VC (with RR equal to 25 br·min⁻¹ and AVD equal to 0 ml), AVD was 0, 100 or 200 ml (with Vreb equal to 35% VC and RR equal to 25 br·min⁻¹) and RR was 10, 25 or 40 br·min⁻¹ (with Vreb equal to 35% VC and AVD equal to 0 ml). AVD was increased by adding rubber tubing between the three-way valve and the mouthpiece.

Prior to rebreathing, the bag was filled with a volume of gas mixture equal to the selected Vreb. The seated subject first breathed ambient air through the mouthpiece. After a few seconds, recording of the rebreathing bag volume and He and C_2H_2 concentrations began. Between 10–20 s later, at the end of a tidal expiration, the subject changed the position of the three-way valve from room air to the bag. Rebreathing manoeuvres started at or near functional residual capacity; subjects rebreathed the predetermined Vreb by emptying and filling the bag with each breath in time with a metronome set to the chosen RR. Each of the seven experimental conditions was repeated six times for each subject.

Statistical analysis

Results were expressed as mean±1 sp. Comparisons between VA and Vt were made by repeated measurements from analysis of variance (Vreb, RR and AVD) and covariance (height). Correlations and regression lines were calculated using the method of least squares [20]. We considered a value of p<0.05 as significant.

Table 1. — Mean±sp of alveolar volume (Va) and lung tissue volume (Vt) under various rebreathing conditions

Rebreathing condition	Vreb % pred VC	RR br·min ⁻¹	AVD ml	VA ml STPD	Vt ml
1	35	25	0	3782	503
				±499	±79
2	20	25	0	3110	466
				±463	±96
3	50	25	0	4081	481
				±559	±79
4	35	10	0	3611	735
				±537	±133
5	35	40	0	3716	461
				±632	±105
6	35	25	100	3812	471
				±672	±70
7	35	25	200	3883	497
				±605	±93

Vreb: rebreathing volume; RR: respiratory rate; AVD: additional deadspace.

Results

Mean and standard deviation of VA and Vt under the various experimental conditions are indicated in table 1, and statistical significance from analyses of variance of the effects of Vreb, RR and AVD on VA and Vt are shown in table 2; the effects of Vreb, RR and AVD on Vt always had height as a significant covariant (p=0.029, 0.026, and 0.019, respectively). Means and standard deviations of individual measurements of Vt for each subject with respect to the seven protocols are shown in table 3.

Because RR had a significant effect on Vt, we determined the regression lines of Vt in relation to height for various RR when Vreb was 35% of VC and AVD

Table 2. – Significance of the effects of changes in rebreathing conditions on alveolar volume and lung tissue volume

	Effect on				
Rebreathing condition	Alveolar volume (VA)	Lung tissue volume (Vt			
Tidal volume (TV)	p<0.0001	NS			
Respiratory rate (RR)	NS	p<0.0001			
Additional deadspace (AVD)	NS	NS			

Ns: not significant.

was 0 ml. Figure 1 shows individual values and regression lines of Vt *versus* height at various RR (r=0.718 for 10 br·min⁻¹, r=0.741 for 25 br·min⁻¹, r=0.745 for 40 br·min⁻¹; df=8; p<0.02 under all conditions).

Significance of correlations between Vt, VA, and Vreb when AVD was maintained at 0 ml and RR




Table 4. – Significance of correlations between lung tissue volume (Vt) alveolar volume (Va) and rebreathing volume (Vreb), at various Vreb without the height covariant

	Vreb				
	20% VC	35% VC	50% VC		
Vreb - Vt	p<0.05	NS	NS		
Va - Vt	NS	p<0.05	p<0.05		
Va - Vreb	p<0.02	p<0.01	p<0.05		

VC: vital capacity; NS: not significant.

Table 3. - Mean±sp of lung tissue volume (ml) for each subject with respect to rebreathing conditions and height (cm)

	Subjects and their heights								
JP 169	GH 179	DD 187	GL 162	MM 162	TC 169	CD 162	TK 182	OP 177	AG 166
487	592	601	434	557	396	402	587	521	458
±51	±84	±79	±22	±57	±51	±70	±43	±51	±69
2 540	615	599	452	327	459	346	464	449	408
±73	±69	±92	±23	±29	±22	±51	±56	±50	±47
600	598	486	415	443	463	422	537	355	495
±66	±60	±47	±47	±48	±41	±45	±82	±42	±71
856	933	886	549	595	759	687	709	790	585
±83	±147	±154	±84	±87	±82	±89	±39	±136	±106
361	615	596	413	477	442	313	584	392	418
±45	±81	±88	±51	±38	±47	±40	±75	±58	±54
417	527	551	464	507	396	390	591	411	461
±53	±37	±82	±63	±71	±45	±51	±76	±78	±45
432	480	656	437	436	484	439	684	470	457
±32	±60	±82	±57	±61	±69	±28	±90	±74	±70
	169 487 ±51 540 ±73 600 ±66 856 ±83 361 ±45 417 ±53 432	169 179 487 592 ±51 ±84 540 615 ±73 ±69 600 598 ±66 ±60 856 933 ±83 ±147 361 615 ±45 ±81 417 527 ±53 ±37 432 480	169 179 187 487 592 601 ±51 ±84 ±79 540 615 599 ±73 ±69 ±92 600 598 486 ±66 ±60 ±47 856 933 886 ±83 ±147 ±154 361 615 596 ±45 ±81 ±88 417 527 551 ±53 ±37 ±82 432 480 656	JP GH DD GL 169 179 187 162 487 592 601 434 ±51 ±84 ±79 ±22 540 615 599 452 ±73 ±69 ±92 ±23 600 598 486 415 ±66 ±60 ±47 ±47 856 933 886 549 ±83 ±147 ±154 ±84 361 615 596 413 ±45 ±81 ±88 ±51 417 527 551 464 ±53 ±37 ±82 ±63 432 480 656 437	JP GH DD GL MM 169 179 187 162 162 487 592 601 434 557 ±51 ±84 ±79 ±22 ±57 540 615 599 452 327 ±73 ±69 ±92 ±23 ±29 600 598 486 415 443 ±66 ±60 ±47 ±47 ±48 856 933 886 549 595 ±83 ±147 ±154 ±84 ±87 361 615 596 413 477 ±45 ±81 ±88 ±51 ±38 417 527 551 464 507 ±53 ±37 ±82 ±63 ±71 432 480 656 437 436	JP GH DD GL MM TC 169 179 187 162 162 169 487 592 601 434 557 396 ±51 ±84 ±79 ±22 ±57 ±51 540 615 599 452 327 459 ±73 ±69 ±92 ±23 ±29 ±22 600 598 486 415 443 463 ±66 ±60 ±47 ±47 ±48 ±41 856 933 886 549 595 759 ±83 ±147 ±154 ±84 ±87 ±82 361 615 596 413 477 442 ±45 ±81 ±88 ±51 ±38 ±47 417 527 551 464 507 396 ±53 ±37 ±82 ±63 ±71 ±45 <	JP GH DD GL MM TC CD 169 179 187 162 162 169 162 487 592 601 434 557 396 402 ±51 ±84 ±79 ±22 ±57 ±51 ±70 540 615 599 452 327 459 346 ±73 ±69 ±92 ±23 ±29 ±22 ±51 600 598 486 415 443 463 422 ±66 ±60 ±47 ±47 ±48 ±41 ±45 856 933 886 549 595 759 687 ±83 ±147 ±154 ±84 ±87 ±82 ±89 361 615 596 413 477 442 313 ±45 ±81 ±88 ±51 ±38 ±47 ±40 417 527	JP GH DD GL MM TC CD TK 169 179 187 162 162 169 162 182 487 592 601 434 557 396 402 587 ±51 ±84 ±79 ±22 ±57 ±51 ±70 ±43 540 615 599 452 327 459 346 464 ±73 ±69 ±92 ±23 ±29 ±22 ±51 ±56 600 598 486 415 443 463 422 537 ±66 ±60 ±47 ±47 ±48 ±41 ±45 ±82 856 933 886 549 595 759 687 709 ±83 ±147 ±154 ±84 ±87 ±82 ±89 ±39 361 615 596 413 477 442 313 584	JP GH DD GL MM TC CD TK OP 169 179 187 162 162 169 162 182 177 487 592 601 434 557 396 402 587 521 ±51 ±84 ±79 ±22 ±57 ±51 ±70 ±43 ±51 540 615 599 452 327 459 346 464 449 ±73 ±69 ±92 ±23 ±29 ±22 ±51 ±56 ±50 600 598 486 415 443 463 422 537 355 ±66 ±60 ±47 ±47 ±48 ±41 ±45 ±82 ±42 856 933 886 549 595 759 687 709 790 ±83 ±147 ±154 ±84 ±87 ±82 ±89 ±39




Fig. 2. – Individual values and regression lines of lung tissue volume versus alveolar volume in ten normal subjects rebreathing at three rebreathing volumes (—— 20% VC, r=0.344; --• 35% VC, r=0.659; •• 50% VC, r=0.655) with 25 br·min⁻¹ respiratory rate and 0 ml additional deadspace.

at 25 br·min⁻¹ is shown in table 4. Figure 2 shows individual values and regression lines of Vt *versus* VA.

Discussion

Our study of normal subjects showed that measurements of Vt were influenced neither by AVD nor by changes in Vreb. However, Vt increased both with height and when RR was low (10 br·min⁻¹).

Additional deadspace

AVD up to 200 ml did not cause any change in Vt. This result is no different from that of Petrini et al. [15]; using a mathematical model of the human lung, they found only a 22 ml (4%) increase in Vt for a 200 ml deadspace, and an 83 ml (14%) increase in Vt for a 600 ml deadspace. Since, in our study, the total deadspace volume (anatomical, apparatus and additional deadspaces) never exceeded one third of Vreb, we may have precluded any demonstrable effect on Vt of increasing AVD. Furthermore, in our study, the effect of increasing AVD is quite different from that of an increase in physiological deadspace, since the tracer gas cannot diffuse across the inorganic material of AVD as it does across the conducting airways.

Rate of rebreathing

Slow RR was associated with a rise in Vt. Vt in the standard condition of rebreathing (Vreb=35% VC, AVD=0 ml) increased from 503 ml for a 25 br·min⁻¹ RR to 735 ml for a 10 br·min⁻¹ RR. KALLAY et al. [13] also found an inverse relationship between Vt and RR and concluded that the time allowed for alveolar mixing is an important determinant of Vt. Part of this increase might be explained by technical artifacts. Average Vt decreased to 627 ml when the fifth and sixth breaths were excluded from the Vt calculation. At a 10 br·min⁻¹ RR these two breaths are obviously affected by C₂H₂ recirculation, as already observed [21]. Unfortunately, using only the second, third, and fourth end-expiratory fractional concentrations leads to a larger variability in the results.

Rebreathing volume

Vreb did not have any effect on Vt in our normal human subjects. Various cofactors may influence the effect of Vreb on Vt: the species, the lung conditions (normal or oedematous), and the end-expiratory lung volume during the rebreathing manoeuvre. Changes in Vreb did not have any effect on Vt in normal dogs, but did have an effect in dogs with pulmonary oedema [5].

In contrast, Vt increases with Vreb in both normal sheep and sheep with pulmonary oedema [6]; this discrepancy may be explained by better access of the tracer gas to the terminal respiratory units of the animal with "low" inspiratory capacity at the functional residual capacity, either under normal conditions (sheep) or under the effects of pulmonary oedema (dog) [6]. KALLAY et al. [13] studied the effect of Vreb on Vt in six normal human subjects keeping the inspired volume and VA constant but with various end-expiratory volumes during the rebreathing manoeuvre. They found an increase in Vt when Vreb increased and the end-expiratory lung volume decreased. By contrast, in our study the end-expiratory lung volume (residual functional capacity) was constant, a difference in experimental conditions which may explain the difference in the effects of Vreb on Vt.

Height

Vt was strongly correlated with the height of the subjects – the taller the subjects, the higher the Vt. Overland et al. [10] related Vt to predicted total lung capacity (TLC) in order to normalize for differences in body size. Crapo et al. [12] normalized TLC by expressing it as TLC/FRC (functional residual capacity). They reasoned that height is the major factor in predicted TLC or FRC and that expressing Vt as fraction of predicted TLC or FRC is a simple way of allowing for height, as lung size depends on the subject's height. This reasoning agrees with the positive correlation also found between Vt and Va in most studies [1, 10–13, 22].

Va depends on both height and Vreb. Therefore, the relationship between VA and Vt may interfere with height. We have shown that Vt was positively correlated with Va when Vreb was maintained at 35 and 50% of VC, and pooling all the data, that Vt was also correlated with VA. Similar results have been observed by Overland et al. [10] in man and by PETERSON et al. [1] in dogs. KALLAY et al. [13] found that when VA was increased from residual volume (RV) by progressively larger inspiratory volume and Vreb, Vt increased 50 ml·l·1 VA. The usual explanation for this effect is that an increase in Vt caused by an increase in VA is related to deeper penetration of the tracer gas in the peripheral pulmonary units where the ratio between tissue volume and gas volume is maximal. Another explanation is that because VA depends on both height and Vreb, the relationship between Vt and Va might be explained by an effect of height on VA and on Vt. Our data in normal human subjects show that Vreb has no effect on Vt and that Vt has height as a covariant in all statistical analyses that we performed. However, KALLAY et al. [13] showed that increasing VA by increasing the end-expiratory volume whilst keeping the inspiratory volume and Vreb constant did not significantly alter Vt. This might be explained by the much narrower range of height of Kallay's subjects compared to ours, which might preclude any detection of the effects of height on Vt. This strongly suggests that the link between Vt and VA is due to a common dependence of VA and Vt on height in normal human subjects when starting to rebreathe from FRC.

In conclusion, our study in normal human subjects shows that Vt is not influenced by an increase in AVD and that Vt increases when RR is low. Whilst changes in Vreb influence VA, they do not affect Vt, suggesting that in normal human subjects and over a wide range of Vreb and RR, the relationship between VA and Vt is probably due to height.

References

- 1. Peterson BT, Petrini MF, Hyde RW, Schreiner BF. Pulmonary tissue volume in dogs during pulmonary edema. J Appl Physiol: Respirat Environ Exercise Physiol, 1978, 44, 782–795.
- 2. Glauser FL, Wilson AF, Carothers L, Higi J, White D, Davis J. Pulmonary parenchymal tissue volume measurements in graded degrees of pulmonary edema in dogs. *Circ Res*, 1975, 36, 229–235.
- 3. Felton CR, Johanson WG Jr. Lung tissue volume during development of edema in isolated canine lung. J Appl Physiol: Respirat Environ Exercise Physiol, 1980, 48, 1038–1044.
- 4. Friedman M, Kaufman SH, Wilkins SA Jr. Analysis of rebreathing measurements of pulmonary tissue volume in pulmonary edema. *J Appl Physiol: Respirat Environ Exercise Physiol*, 1980, 48, 66–71.
- 5. Huchon GJ, Lipavsky A, Pangburn P, Hoeffel JM, Jibelian G, Murray JF. Factors affecting tissue volume measurements in normal and edematous dog lungs. *J Appl Physiol*, 1985, 59, 1548–1554.
- 6. Huchon GJ, Lipavsky A, Hoeffel JM, Murray JF. Rebreathing lung tissue volume of sheep with normal and edematous lungs. J Appl Physiol, 1986, 61, 1132–1138.
- 7. Sackner MA, Greeneltch D, Heiman MS, Epstein S, Atkins N. Diffusing capacity, membrane diffusing capacity, capillary blood volume, pulmonary tissue volume, and cardiac output measured by a rebreathing technique. *Am Rev Respir Dis*, 1975, 111, 157–165.
- 8. Farney RJ, Morris AH, Gardner RM, Armstrong JD Jr. Rebreathing pulmonary capillary and tissue volume in normals after saline infusion. *J Appl Physiol: Respirat Environ Exercise Physiol*, 1977, 43, 246–253.
- 9. Sackner MA, Markwell G, Atkins N, Birch SV, Fernandez RJ. Rebreathing techniques for pulmonary capillary blood flow and tissue volume. *J Appl Physiol: Respirat Environ Exercise Physiol*, 1980, 49, 910–915.
- 10. Overland ES, Gupta RN, Huchon GJ, Murray JF. Measurement of pulmonary tissue volume and blood flow in persons with normal and edematous lungs. *J Appl Physiol: Respirat Environ Exercise Physiol*, 1981, 51, 1375–1383.
- 11. Crapo RO, Crapo JD, Morris AH. Lung tissue and capillary blood volumes by rebreathing and morphometric techniques. *Respir Physiol*, 1982, 49, 175–186.
- 12. Crapo RO, Morris AH, Gardner RM. Reference values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume. *Clin Respir Physiol*, 1982, 18, 893–899.
- 13. Kallay MC, Hyde RW, Fahey PJ, Utell MJ, Peterson BT, Ortiz CR. Effect of the rebreathing pattern on pulmonary tissue and capillary blood flow. *J Appl Physiol*, 1985, 58, 1881–1894.
- 14. Cander L, Forster RE. Determination of pulmonary parenchymal tissue volume and pulmonary capillary blood

flow in man. J Appl Physiol, 1959, 14, 541-551.

15. Petrini MF, Peterson BT, Hyde RW. - Lung tissue volume and blood flow by rebreathing: theory. J Appl Physiol: Respirat Environ Exercise Physiol, 1978, 44, 795-802.

 Staub NC. - Clinical use of lung water measurements. Chest, 1986, 90, 588-594.

17. Hook C, Meyer M. – Pulmonary blood flow, diffusing capacity and tissue volume by rebreathing: theory. *Respir Physiol*, 1982, 48, 255–279.

18. Burma GM, Saidel GM. – Pulmonary blood flow and tissue volume: model analysis of rebreathing estimation methods. *J Appl Physiol: Respirat Environ Exercise Physiol*, 1983, 55, 205–211.

19. Cander L. - Solubility of inert gases in human lung tissue. J Appl Physiol, 1959, 14, 538-540.

20. Zar JH. - In: Biostatistical analysis. Prentice-Hall, Englewood Cliffs, NJ, 1974.

21. Triebwasser JH, Johnson RL Jr, Burpo RP, Campbell JC, Reardon WC, Blomquist CG. – Noninvasive determination of cardiac output by a modified acetylene rebreathing procedure utilizing mass spectrometer measurements. Aviat Space Environ Med, 1977, 48, 203–209.

22. Glauser FL, Wilson AF. – Pulmonary parenchymal tissue volume in normal subjects. The effect of age and sex. *Chest*, 1977, 72, 207–212.

Effets des conditions de "rebreathing" et de la taille corporelle sur le volume tissulaire pulmonaire chez l'homme normal. J.M. Polianski, P.D. Vivet, T.C. Chinet, S.I. Labrune, D.G. Henzel, G.J. Huchon.

RÉSUMÉ: Pour évaluer les conséquences des variations du type respiratoire inhérent à la maladie pulmonaire sur la mesure du volume du tissu pulmonaire par "rebreathing" (Vt), nous étudié 10 sujets humains normaux, chez qui nous avons apprécié les effets des modifications du volume de "rebreathing" (Vreb), du volume de l'espace mort additionnel (AVD), de la fréquence respiratoire (RR), et de la taille des sujets. Vt et le volume alvéolaire (VA) ont été déterminés à partir des concentrations d'acétylène et d'hélium, à la fin du volume courant. Nous avons exécuté des mesures de Vt en utilisant différentes combinaisons de Vreb (20, 35 et 50% de la capacité vitale prédite), de AVD (0, 100 et 200 ml) et de RR (10, 25 et 40 resp·min-1). Seuls les RR bas (10 resp·min-1) entraînaient une augmentation du Vt (p<0.001). Une augmentation de Vreb entraîne une augmentation de Va, mais pas de Vt. Va et Vt sont en corrélation positive avec la taille des sujets. Nous concluons que, chez les sujets normaux, Vt augmente: 1) avec la taille des sujets; et 2) en cas de rythme respiratoire lent. L'interprétation des résultats de Vt doit donc prendre ces deux variables en considération.

Eur Respir J., 1989, 2, 78-83.